How to deal with the resistance problem of the third-generation targeted drug platinib?

When patients experience continued tumor growth or recurrence after receiving platinib treatment, they should report it to their doctor in a timely manner. Doctors will determine whether platinib resistance is based on clinical symptoms, physical examination results, and possible imaging examinations. This step is crucial because it provides a basis for subsequent adjustment of treatment strategies.

After confirming resistance, doctors need to conduct detailed analysis of the resistance mechanism. Platinib resistance mechanisms are mainly divided into two types: resistance caused by target mutations and resistance caused by abnormal activation of kinase signaling pathways. For target mutations, the specific mutation type can be clarified through genetic testing, so that corresponding targeted therapy drugs can be selected. For example, for resistance caused by ALK mutations, other ALK inhibitors can be tried.

For drug resistance caused by abnormal activation of kinase signaling pathways, the combined use of other anti-tumor drugs other than platinib can be considered to inhibit the abnormally activated signal transduction pathways. This combination therapy may help overcome drug resistance and improve treatment efficacy.

For drug-resistant patients who currently have no effective treatment options, participating in a clinical trial targeting platinib resistance may be a good option. Clinical trials often provide new drugs or treatment options in the hope of achieving better therapeutic effects.

After drug resistance occurs, in addition to adjusting drug therapy, the patient's physical condition and mental health also need to be comprehensively considered. It is very important to actively adjust your mentality and maintain good living habits, diet and exercise. At the same time, you can also seek support such as psychological counseling to help patients better cope with the life and psychological pressure caused by drug resistance.